Brachial plexopathy as a complication of COVID-19

Catherine Young Han,1 Andrew M Tarr,2 Alexandra N Gewirtz,2 Ulrike W Kaunzner,3 Paula Roy-Burman,1 Todd S Cutler,1 Daniel JL MacGowan3

SUMMARY
COVID-19 affects a wide spectrum of organ systems. We report a 52-year-old man with hypertension and newly diagnosed diabetes mellitus who presented with hypoxic respiratory failure due to COVID-19 and developed severe brachial plexopathy. He was not treated with prone positioning respiratory therapy. Associated with the flaccid, painfully numb left upper extremity was a livedoid, purpuric rash on his left hand and forearm consistent with COVID-19-induced microangiopathy. Neuroimaging and electrophysiological data were consistent with near diffuse left brachial plexitis with selective sparing of axillary, suprascapular and pectoral fascicles. Given his microangiopathic rash, elevated D-dimers and paucifascicular plexopathy, we postulate a patchy microvascular thrombotic plexopathy. Providers should be aware of this significant and potentially under-recognised neurologic complication of COVID-19.

BACKGROUND
The current COVID-19 pandemic has resulted in approximately 57.8 million cases and 1.3 million deaths.1 Although COVID-19 was originally seen as a predominantly respiratory illness, our understanding of its impact on multiple organ systems has evolved. It is often accompanied by a variety of neurologic symptoms such as headache, anosmia, confusion and altered mental status.2 Ischaemic vascular events have been frequently observed.3 4 Less commonly, neurologic presentations such as Guillain-Barre syndrome, necrotising haemorrhagic encephalopathy and focal status epilepticus have also been described.5–7 Here, we seek to add to our understanding of COVID-19 by presenting a case of brachial plexopathy.

CASE PRESENTATION
A 52-year-old man with hypertension and newly diagnosed diabetes mellitus presented to our emergency department in March 2020 after 4 days of cough, shortness of breath, fatigue and myalgias. He had no sick contacts or recent travel. He was febrile (38.6°C), tachycardic, tachypneic and hypoxic (90% on room air). At the time, neurologic examination was unremarkable. Chest X-ray demonstrated extensive bilateral opacities consistent with multifocal pneumonia. Diagnosis of COVID-19 was made by detection of SARS-CoV-2 nucleic acid by reverse transcription PCR.

The patient’s oxygen requirements escalated, and he was intubated for respiratory failure within 24 hours of admission. For COVID-19-directed therapy, he received 5 days of hydroxychloroquine and two doses of a study drug (sarilumab vs placebo) on days 8 and 24. His course was complicated by transient renal failure without need for dialysis, Enterobacter pneumonia and Pseudomonas cystitis (both treated with piperacillin/tazobactam) and a hypercoagulable state with elevated D-dimers (figure 1). He was treated continuously with high-dose prophylactic enoxaparin, 30–40mg two times per day. During intubation, he had multiple, uncomplicated central venous and arterial lines. There was no left axillary arterial catheterisation, and he never received prone positioning respiratory therapy. On day 22, he underwent percutaneous tracheostomy.

On day 24, a livedoid, retiform, purpuric rash was noted on the left hand and forearm (figure 2). Dermatology was consulted. The rash was deemed characteristic of COVID-19-induced thrombotic microvascular injury based on the department’s case series.8 A biopsy was therefore not performed.

Within 4 days, the patient was noted to have severe weakness of the left upper extremity and neuropathic pain in the left hand and forearm. Neurology was consulted. On examination, tone was absent in the left hand, wrist and elbow. The left biceps reflex was reduced with absence of the left brachioradialis and triceps reflexes. Pin and thermal sensation were absent over the entire left forearm and hand, with presence of tactile allodynia. Strength was reduced as follows: biceps 2/5, triceps 0/5, wrist and finger extensors 0/5, wrist and finger flexors 3/5, forearm pronation 3/5, forearm supination 2/5, superficial and deep finger flexors 3/5 and intrinsic hand muscles 3/5. The left deltoid, infraspinatus and pectoral muscles were strong at 5/5. There was no scapular winging (table 1).

INVESTIGATIONS
Subsequent chest X-ray showed resolving multifocal pneumonia without elevation of the left hemidiaphragm.

MRI of the left brachial plexus with and without intravenous contrast revealed T2 hyperintensity and thickening of the entire brachial plexus without contrast enhancement (figure 3A). There was enhancement and T2 hyperintensity of the left serratus anterior reflecting acute denervation oedema (figure 3B).

Nerve conduction studies (NCSs) and needle electromyography (EMG) were performed on day 49 (online supplemental tables 1A, 2A, 3A). NCS revealed markedly reduced left median and ulnar compound muscle action potential response amplitudes with slowing of motor conduction velocities due to axon loss. The left-sided median, ulnar, radial, musculocutaneous and medial antebrachial cutaneous responses were all absent. Needle EMG
of muscles in the left upper extremity showed fibrillations and positive sharp waves in all muscles except the deltoid, where examination was normal. Recruitment was absent in the left triceps, brachioradialis, extensor carpi radialis, extensor digitorum communis and extensor indicis. Recruitment was reduced in the remaining assessed muscles. A selective fascicular biopsy of the brachial plexus was felt to be against the best interests of the patient.

Laboratory studies were sent to evaluate vasculitides and coagulation disorders. Factor VIII activity was elevated (184%; reference 50%–150%) and protein S activity was mildly reduced (65%; reference 75%–125%). Work-up was otherwise unremarkable (online supplemental table 4).

DIFFERENTIAL DIAGNOSIS

Injury to the brachial plexus can be caused by a variety of mechanisms including trauma/compression, autoimmune reactions, direct viral infection and microvascular ischaemia.⁹ Traumatic plexopathies are occasionally seen secondary to stretch injury, often from intraoperative positioning and typically with good recovery of symptoms.¹⁰ Prone positioning, frequently employed in the management of acute respiratory distress syndrome, has been reported to cause neurapraxic brachial plexopathy from pressure injury.¹¹¹² Brachial plexus injury has also been reported in conjunction with trauma to the axillary artery, including complications of axillary arterial lines (eg, local thromboses, haematomas and pseudoaneurysms).¹³¹⁴ In our case, traumatic and compressive aetiologies were ruled out. The patient was never prone, nor his left arm was ever hyperabducted or cannulated by an axillary line. Additionally, there was no evidence of focal trauma or compression on MRI. The severe weakness and numbness with axonotmetic electrodiagnostic findings eliminate a stretching neurapraxic injury.

Given his concurrent rash, vasculitis of the brachial plexus was considered. Medium and small vessel vasculitides can cause inflammation of the epineural arteries of the vasa nervorum with subsequent thrombosis and ischaemia.¹⁵–¹⁸ However, most vasculitides present with mononeuritis or mononeuritis multiplex; vasculitis-associated plexopathies are rare.¹⁹ In our patient, autoimmune and vasculitis labs were unremarkable. His new diagnosis of diabetes mellitus prompted consideration of diabetic radiculoplexus neuropathy. Most cases, however, progress to involve the contralateral side or are associated with lumbosacral plexus disease.²⁰

Direct viral invasion of the plexus, as with varicella-zoster virus (VZV)-associated plexopathy, was also plausible. VZV can rarely infect the plexus with a radial nerve-predominant palsy, however the distribution of weakness and rash would be expected to colocalise.²¹²² In this case, weakness was found in muscle groups beyond the distribution of the rash. Another possibility was Parsonage-Turner syndrome (or neuralgic amyotrophy) in a postviral setting. Classically, patients report

---

Table 1  Neurologic examination of left upper extremity—inpatient examination and postdischarge follow-up

| Tone       | Hand | Inpatient examination | Postdischarge follow-up |
|------------|------|-----------------------|-------------------------|
|            | Absent | Reduced               | Reduced                 |
| Reflexes   | Absent | Absent                | Absent                  |
| Sensation  | Absent | Reduced               | Reduced                 |

---

Figure 1  D-dimer levels in the patient over the course of his hospitalisation. The black arrow indicates the first appearance of the microthrombotic rash. Reference range: 0–229 ng/mL.

Figure 2  Livedoid, retiform purpura of the left hand and forearm (A) on day 24, (B) on day 45 (day of initial neurological consultation) and (C) on day 50 (day following EMG/NCS). (D) The rash did not involve the left upper arm, despite weakness of these muscle groups. EMG, electromyography; NCS nerve conduction study.
Case report

sudden-onset, severe but self-limited unilateral shoulder pain. Weakness, generally localised to the upper proximal limb, is noted 1–2 weeks after onset of pain. Neuralgic amyotrophy of the brachial plexus has been described in association with COVID-19, with the proposed mechanism of action being a COVID-19 immune-mediated inflammation. However, the focal demyelination that would be seen with this process differs from the patchy pattern of axonotmesis seen in our patient with complete sparing of axillary, pectoral and suprascapular fascicles. The complete sparing of some fascicles and severe denervation of other fascicles that run through the same trunks and cords suggest a microvascular paucifascicular infarction due to thrombosis of the vasa nervorum supplying the brachial plexus, thereby causing nerve ischaemia and infarction.

TREATMENT

His wrist was splinted to prevent contractures. He received physical therapy, and his pain improved with gabapentin, oxycodeone and acetaminophen.

OUTCOME AND FOLLOW-UP

The patient was transferred to a rehabilitation unit on day 69 and was discharged home on day 106 of his hospitalisation. A neurological follow-up examination and EMG were conducted 3 months after discharge. His neuropathic pain had resolved.

DISCUSSION

To our knowledge, this is the first reported case of brachial plexopathy associated with COVID-19 in a patient never placed in the prone position. We propose that a COVID-19-induced hypercoagulable state resulted in microthrombi which occluded portions of the vasa nervorum supplying the brachial plexus, thereby causing nerve ischaemia and infarction.

COVID-19 can cause a hypercoagulable state due to activation of the coagulation cascade and complement system. Laboratory abnormalities include elevated fibrinogen, elevated D-dimer and changes to prothrombin time (PT), activated partial thromboplastin time (aPTT), and international normalized ratio (INR). Multiple reports have described the high likelihood of pulmonary embolism and deep venous thrombosis in...
COVID-19, with Klok et al reporting a 49% incidence of large-vessel thrombotic complications in critically ill patients with COVID-19. Additionally, multiple reports have described the formation of microthrombi in small vessels affecting the lungs, heart and skin. Megro et al described COVID-19 patients with retiform, purpuric lesions identical to those in this case. These skin lesions, on immunohistochemical staining, showed thrombotic vascopathy with significant deposition of C5b-9 in the microvasculature.

In this patient, prior to the onset of his rash, D-dimers were elevated between 2400 ng/mL and 3000 ng/mL, with abnormal factor VIII and protein S levels supporting the presence of an acquired prothrombotic state during acute viral infection. Electrophysiology showed a combination of complete or partial axonotmesis of most but not all of the motor fascicles, supporting a patchy infarction pattern of the brachial plexus. For example, though both radial and axillary nerves are branches of the posterior cord of the brachial plexus, muscles innervated by the radial nerve were affected, while those by the axillary nerve were spared. Considering the prothrombotic state, these findings support a variable microthrombosis of the vasa nervorum as has also been hypothesised by Needham et al in a recent case series of patients with COVID-19 and mononeuritis multiplex.

Further investigations should examine microthrombi formation as an important mechanism by which COVID-19 affects the peripheral nervous system and also explore more effective therapy against microthrombi formation in COVID-19 infection.

Contributors
C HY contributed to writing/manuscript preparation, writing the initial draft, making critical revisions and creating figures/tabels. She aided with notices and trade marks are retained. Provenance and peer review Patient consent for publication Competing interests Funding

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Funding
The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests
None declared.

Patient consent for publication
Obtained.

Provenance and peer review
Not commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

REFERENCES
1 Weekly epidemiological update – 24 November 2020. World Health Organization 2020.
2 Asadi-Pooya AA, Simari L. Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci 2020;413:116832.
3 Oksley TJ, Mocco J, Majidi S, et al. Large-Vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med 2020;382:e660.
4 Merkler AE, Parikh NS, Mir S, et al. Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza. JAMA Neurol 2020;77:1366–72.
5 Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: a case report. J Clin Neurosci 2020;76:233–5.
6 Vollono C, Rollo E, Romozzi M, et al. Focal status epilepticus as unique clinical feature of COVID-19: a case report. Seizure 2020;78:109–12.
7 Poyiadji N, Shahn G, Noujaim D, et al. COVID-19 associated acute hemorrhagic necrotizing encephalopathy: imaging features. Radiology 2020;296:E119–20.
8 Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 2020;220:1–13.
9 Zakrzasek EM, Kanadikar N. Brachial plexopathy: differential diagnosis and management. American Academy of Physical Medicine and Rehabilitation.
10 Ben-David B, Stahl S. Prognosis of intraoperative brachial plexus injury: a review of 22 cases. Br J Anaesth 1997;79:440–5.
11 Goettler CE, Pyor JP, Reilly PM. Brachial plexopathy after prone positioning. Crit Care 2002;6:540–2.
12 Diprose WK et al. Bilateral upper limb neuropathies following prone ventilation for COVID-19 pneumonia. Neurology: Clinical Practice 2020.
13 Kuo F, Park J, Chow K, et al. Avoiding peripheral nerve injury in arterial interventions. Diagn Interv Radiol 2019;25:380–91.
14 Graham JM, Mattox KL, Feliciano DV, et al. Vascular injuries of the axilla. Ann Surg 1982;195:232–8.
15 Blaes F. Diagnosis and therapeutic options for peripheral vasculitic neuropathy. Ther Adv Musculoskelet Dis 2015;7:45–55.
16 Naseri Alavi SA, Meshkini M, Poulatk T, et al. Microscopic polyangiitis complicated with bilateral brachial plexopathy: a case report and review of the literature. Rheumatol Int 2016;36:997–1001.
17 Raz I, Leidersdorf E, Kleinman Y. Acute bilateral brachial plexus neuritis associated with hypersensitivity vasculitis. A case report and review of literature. Clin Wochenschr 1985;63:643–5.
18 Analasak M, Karaali K, Cevikol C, et al. Mr imaging findings in brachial plexopathy with thoracic outlet syndrome. AJNR Am J Neuroradiol 2010;31:410–7.
19 Imboden JB. Involvement of the peripheral nervous system in polyarteritis nodosa and antineutrophil cytoplasmic Antibodies-Associated vasculitis. Rheum Dis Clin North Am 2017;43:633–9.
20 Massie R, Mauermann ML, Staff NP, et al. Diabetic cervical radiculoplexus neuropathy: a distinct syndrome expanding the spectrum of diabetic radiculoplexus neuropathies. Brain 2012;135:3074–88.
21 Jeevarethinam A, Ihuoma A, Ahmad N. Herpes zoster brachial plexopathy with hypersensitivity vasculitis. A case report and review of literature. Klin Wochenschr 1985;63:643–5.
22 Siepmann T, Kitzler HH, Lueck C, et al. Spinal and brachial plexus brachial plexitis (Parsonage Turner Syndrome, brachial neuropathy, brachial radiculitis). StatPearls 2020.
23 Blaes F. Diagnosis and therapeutic options for peripheral vasculitic neuropathy. Ther Adv Musculoskelet Dis 2015;7:45–55.
24 Feinberg JH, Radecki J. Parsonage-turner syndrome. AJNR Am J Neuroradiol 2010;31:410–7.
25 Ortiz Torres M, Gudlavalleti A, Mesfin FB. Brachial plexitis (Parsonage Turner syndrome, brachial neuropathy, brachial radiculitis). StatPearls 2020.
26 Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
27 Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 2020;18:1747–51.
28 Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020;18:1023–6.
29 Klok FA, Krup M, van der Meer NJM. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020.
30 Klok FA, Krup M, van der Meer NJM. Incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res 2020;191:148–50.
31 Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020;46:1089–98.
32 Luo W, Wang Y, Li X, et al. Clinical characteristics of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
33 Liu PP, Blet A, Smyth D, et al. The science underlying COVID-19: implications for the cardiovascular system. Circulation 2020;142:68–78.
34 Ackermann M, Verleden SE, Kuehnel M. Pulmonary vascular Endotheliitides, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020.
35 Goeminne B, van Wissen M, van de Wegen C, et al. Review: viral infections and mechanisms of thrombosis and bleeding. J Med Virol 2020;82:1680–96.
36 Needham E, Newcombe V, Michel A. Mononeuritis multiplex: an unexpectedly common feature of severe COVID-19. medRxiv 2020.
